When was Viralytics founded?

Viralytics was founded in 2006 and raised its 1st funding round 8 years after it was founded.

Where is Viralytics located?

Viralytics is headquartered in Sydney, Australia.

How many employees does Viralytics have?

As of Mar 01, 2026, the latest employee count at Viralytics is 200 - 499.

Is Viralytics a funded company?

Viralytics is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 30, 2014.

When was the latest funding round of Viralytics?

Viralytics' latest funding was a $***** Post IPO round on Jan 08, 2018, with participation from 1 investor.

Where does Viralytics rank among its competitors?

Viralytics ranks 1349th amongst 3327 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Viralytics?

Viralytics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Viralytics - 2026 Company Profile, Funding & Competitors

Q: Is Viralytics an acquired company?

Viralytics got acquired by Merck on Feb 21, 2018.

Viralytics is an acquired company based in Sydney (Australia), founded in 2006. It operates as a Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer.. Viralytics has raised an undisclosed amount in funding. The company has 3327 active competitors, including 1122 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Viralytics, acquired by Merck in February 2018, is focused on developing oncolytic virotherapy for the treatment of a wide range of cancers. Its lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus (RNA virus) Type A21 (CVA21). It is being evaluated in patients with Melanoma (Phase 2/3); Non-muscle invasive bladder cancer (Phase 1) and one combination study with Keytruda. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells. Their lead candidate in combination with Keytruda had shown positive Phase 1b trial results in patients with late-stage melanoma.

Website: viralytics.com
Social

Key Metrics

Founded Year

2006

Location

Sydney, Australia

Stage

Acquired

Latest Funding Round

Post IPO, Jan 08, 2018, $*****

Investors

VenBio & 1 more

Ranked

1349^th among 3327 active competitors

Employee Count

200 - 499 as on Mar 01, 2026

Similar Companies

Jazz Pharmaceuticals & 3017 more

Exit Details

Acquired by Merck (Feb 21, 2018)

View Viralytics' full profile

Viralytics got acquired by Merck on Feb 21, 2018 at an acquisition amount of $*****.

Click here to take a look at Viralytics's acquisition in detail

Viralytics has raised funding over 4 rounds. Its first funding round was on Jan 30, 2014. Its latest funding round was a Post IPO round on Jan 08, 2018 for $*****. 1 investor participated in its latest round. Viralytics has 2 institutional investors.

Here is the list of recent funding rounds of Viralytics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2018	4119564	Post IPO	5307119	3255964	4056510	8852796
Jan 25, 2016	7850640	Post IPO	1305227	2487146	6258016	8569999
Dec 14, 2015	5065331	Post IPO	2443653	5453300	8869487	3717564

Access funding benchmarks and valuations. Sign up today!

View details of Viralytics's funding rounds and investors

Viralytics' employee count trend

Viralytics has 200 - 499 employees as of Mar 26. Here is Viralytics's employee count trend over the years:

Uncover Viralytics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Viralytics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Viralytics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1349th	Viralytics 2006, Sydney (Australia), Acquired	Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer.	-	VenBio, Lepu Medical Technology	36/100